zuma-3: impact of prior blinatumomab and allosct
Published 2 years ago • 94 plays • Length 3:49Download video MP4
Download video MP3
Similar videos
-
1:54
final results of the gimema lal2317 trial: sequential chemotherapy blinatumomab for ph- b-all
-
1:35
outcomes of allosct following blinatumomab in children and young adults with r/r b-all
-
2:48
results from a subgroup analysis of zuma-3 and the efficacy of brexu-cel in r/r b-all
-
7:57
two-year follow-up of zuma-3: safety and efficacy of brexu-cel in patients with r/r b-all
-
1:39
an update on the gimema lal2317 trial: sequential chemotherapy blinatumomab for ph-like all
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
4:19
blinatumomab to achieve remission and consolidation with haplosct for pediatric all
-
4:38
3m™ snap™ therapy system application & mechanism of action (moa)
-
31:59
cancer immunotherapy research updates panel at 2019 cri immunotherapy patient summit in boston
-
4:13
real-world outcomes of patients with r/r b-all treated with blinatumomab and inotuzumab ozogamicin
-
2:26
optimizing blinatumomab for b-all
-
0:54
zuma-3 end of phase i results: axi-cel for r/r all
-
3:59
3-year follow-up from the transform trial: liso-cel is superior to soc in r/r dlbcl
-
6:24
zuma-3 study update: brexucabtagene autoleucel for r/r all
-
1:29
blinatumomab in combination with checkpoint inhibitors for all
-
1:35
neuf: real-world data on blinatumomab for all
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
1:37
the importance of mrd assessment before allosct in all
-
2:04
treatment approaches to ph-like all: challenges and future outlooks
-
2:26
zuma-5: high orr and cr for r/r inhl with axi-cel
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all